{"nctId":"NCT00412516","briefTitle":"Determining Long-Term Safety and Efficacy of Japanese Encephalitis Vaccine When Given With Measles Vaccine","startDateStruct":{"date":"2006-12"},"conditions":["Encephalitis, Japanese B"],"count":519,"armGroups":[{"label":"Group 1","type":"OTHER","interventionNames":["Biological: Live attenuated SA 14-14-2 vaccine"]},{"label":"Group 2","type":"EXPERIMENTAL","interventionNames":["Biological: Live attenuated SA 14-14-2 vaccine"]},{"label":"Group 3","type":"OTHER","interventionNames":["Biological: Live attenuated SA 14-14-2 vaccine"]}],"interventions":[{"name":"Live attenuated SA 14-14-2 vaccine","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participant was enrolled in the JEV01 study previously conducted at RITM.\n* Participant completed his/her vaccination schedule for the JEV01 study previously conducted at RITM.\n* Participant's blood test results from JEV01 study indicate that he/she had seroconverted to measles vaccination.\n* Participant's parents or legal guardian are/is willing to provide signed informed consent.\n\nExclusion Criteria:\n\n* Participant was withdrawn from the JEV01 study for any reason.\n* Receipt of immune globulin or other blood products within 6 months of study (JEV02) entry or receipt of injected or oral corticosteroids or other immune modulator therapy (except routine vaccines) within 4 weeks of study (JEV02) entry.\n* Any condition that in the opinion of the investigator, would interfere with the evaluation of the study objectives.","healthyVolunteers":true,"sex":"ALL","minimumAge":"20 Months","maximumAge":"36 Months","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Measles Seropositivity at 24 and 36 Months","description":"Seropositivity defined as an anti-MV IgG concentration of 120 mIU/mL determined with the Siemens ELISA","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.92","spread":null},{"groupId":"OG001","value":"95.75","spread":null},{"groupId":"OG002","value":"94.37","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.62","spread":null},{"groupId":"OG001","value":"91.39","spread":null},{"groupId":"OG002","value":"91.04","spread":null}]}]}]},{"type":"SECONDARY","title":"Measles Seropositivity at 12 Months","description":"Seropositivity defined as an anti-MV IgG concentration of 120 mIU/mL determined with the Siemens ELISA","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87.64","spread":null},{"groupId":"OG001","value":"87.32","spread":null},{"groupId":"OG002","value":"87.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Seropositive Rate for Japanese Encephalitis (JE) Antibody in Infants in the Philippines Who Received Measles Vaccine (MV) Before, With, or After SA 14-14-2 JE Vaccination by Month After JE Vaccination.","description":"\"Seropositive\" defined as a person with neutralizing antibody against JE virus at a titer â‰¥ 1:10 in a 50% plaque-reduction neutralizing assay (PRNT-50)","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.4","spread":null},{"groupId":"OG001","value":"83.5","spread":null},{"groupId":"OG002","value":"86.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81.1","spread":null},{"groupId":"OG001","value":"83.8","spread":null},{"groupId":"OG002","value":"80.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79.3","spread":null},{"groupId":"OG001","value":"82.7","spread":null},{"groupId":"OG002","value":"81.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Neutralizing Antibody Titer to Japanese Encephalitis (JE) Virus in Infants in the Philippines Who Received Measles Vaccine (MV) Before, With, or After SA 14-14-2 JE Vaccination by Month After JE Vaccination.","description":"Neutralizing antibody titer determined using a 50% plaque-reduction neutralizing assay (PRNT-50) for JE virus","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"108","spread":null},{"groupId":"OG001","value":"83","spread":null},{"groupId":"OG002","value":"77","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null},{"groupId":"OG001","value":"64","spread":null},{"groupId":"OG002","value":"70","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null},{"groupId":"OG001","value":"47","spread":null},{"groupId":"OG002","value":"58","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":93},"commonTop":[]}}}